Catalyst OrthoScience, a medical technology leader focused on shoulder arthroplasty, announced it has surpassed 10,000 total shoulder arthroplasty (TSA) procedures as it closes $20 million in equity and venture debt financing with funding partners RC Capital, Mutual Capital Partners and Bridge Bank.
The 10,000 completed Catalyst TSA procedures reaffirms the choice made by surgeons and their patients at the forefront of shoulder arthroplasty. And this milestone and financial investment position Catalyst for accelerated growth and continued innovation in the shoulder arthroplasty market. Plus, the company is set up for the next stage of commercial adoption, empowering it to expand its distribution channel, further invest in talent and training, launch new products, and solidify its position as a leading innovator.
KEY QUOTES:
“Catalyst has made significant progress since its first case in 2016. Our unique ability to blend true innovation with unmatched efficiency and predictable outcomes is transforming an industry that has long been burdened by solutions that introduce inefficiencies and inflate procedural costs without also delivering improved patient outcomes. At Catalyst, we’re closing those gaps with our single-tray systems, proprietary instrumentation, fewer surgical steps, and purposefully designed implants. This is increasingly important as procedures shift to ambulatory surgery centers (ASC) where there is a growing desirability for solutions that reduce case turnaround times and sterilization costs, limit storage space needs, and ease the workload on the surgical team.”
-Carl O’Connell, CEO of Catalyst
“Catalyst is a unique company in a fast-growing sector. This funding will allow the company to further its mission to improve shoulder arthroplasty for surgeons and patients across the continuum of care.”
-Carter McNabb, Managing Partner at RC Capital, and Catalyst board member
“Bridge Bank is pleased to support Catalyst as it surpasses this important milestone and positions itself for future growth and continued advancement in patient care.”
-Bill Wickline, Managing Director in the Life Sciences Group at Bridge Bank
